ACE inhibitors versus ARBS in the treatment of hypertension: efficacy and safety in blood pressure control and prevention of cardiovascular events in adults
DOI:
https://doi.org/10.69849/bkgeth42Keywords:
arterial hypertension, ACE inhibitors, ARBs, efficacy, safetyAbstract
Systemic arterial hypertension is a chronic disease with high global prevalence, characterized by persistent elevation of blood pressure and associated with serious cardiovascular and renal events, such as stroke, acute myocardial infarction, heart failure, and chronic kidney disease. Pharmacological management primarily involves angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), widely recommended as first-line therapies. Although both classes show similar efficacy in blood pressure control and prevention of cardiovascular outcomes, ACEIs are associated with a higher incidence of adverse effects, such as persistent cough and angioedema, whereas ARBs demonstrate better tolerability. Evidence also suggests that specific populations, including elderly patients with type 2 diabetes or those with heart failure, may benefit differently from each class. This integrative review aims to compare the efficacy and safety of ACEIs and ARBs, providing support for individualized therapy and evidence-based clinical decision-making.
References
AL-JANABI, F. L. M. et al. Risk of developing hyperkalemia in patients with hypertension treated with combination antihypertensive therapy: a retrospective register-based study. Hypertension Research, v. 48, n. 1, p. 378-387, 2025.
AN, J. et al. Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens. Hypertension, v. 77, n. 1, p. 103-113, 2021.
BARROSO, W. K. S. et al. Diretrizes brasileiras de hipertensão arterial – 2021. Arquivos Brasileiros de Cardiologia, v. 116, n. 3, p. 516-658, 2021.
BROOK, R. D. et al. Cardiovascular benefits of angiotensin-converting enzyme inhibition plus calcium channel blockade in patients achieving tight blood pressure control and with resistant hypertension. American Journal of Hypertension, v. 34, n. 5, p. 531-539, 2021.
CHEN, R. J.; SUCHARD, M. A.; KRUMHOLZ, H. M.; SCHUEMIE, M. J.; SHEA, S.; DUKE, J.; PRATT, N.; REICH, C. G.; MADIGAN, D.; YOU, S. C.; RYAN, P. B.; HRIPCSAK, G. Comparative first-line effectiveness and safety of ACE inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension, 2021. Disponível em: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16667. Acesso em: 18 set. 2025.
COCA, A. et al. Single-pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit? European Journal of Internal Medicine, v. 126, p. 16-25, 2024.
EGAN, B. M. et al. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Pressure, v. 31, n. 1, p. 164-168, 2022.
ELSAYED, N. A. et al. Cardiovascular disease and risk management: standards of care in diabetes – 2024. Diabetes Care, v. 47, supl. 1, p. S179-S218, 2024.
ESC – EUROPEAN SOCIETY OF CARDIOLOGY. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 2024. Disponível em: https://academic.oup.com/eurheartj/article/45/34/3415/7744579. Acesso em: 18 set. 2025.
GEORGES, C. M. G. et al. Drug adherence and psychological factors in patients with apparently treatment-resistant hypertension: yes but which ones? Journal of Clinical Hypertension, v. 24, n. 11, p. 1436, 2022.
GNANENTHIRAN, S. R. et al. Association of low-dose triple combination therapy vs usual care with time at target blood pressure. JAMA Cardiology, v. 7, n. 6, p. 645-650, 2022.
HU, Y.; LIANG, L.; LIU, S.; KUNG, J. Y.; BANH, H. L. Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: a systematic review and network meta-analysis. Journal of Clinical Hypertension, v. 25, n. 8, p. 661– 688, 2023. DOI: 10.1111/jch.14695. Disponível em: https://doi.org/10.1111/jch.14695. Acesso em: 18 set. 2025.
KROGAGER, M. L. et al. Risk of developing hypokalemia in patients with hypertension treated with combination antihypertensive therapy. Hypertension, v. 75, n. 4, p. 966-972, 2020.
LU, Y. et al. Analysis of dual combination therapies used in treatment of hypertension in a multinational cohort. JAMA Network Open, v. 5, n. 3, e223877, 2022.
MCEVOY, J. W. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, v. 45, n. 38, p. 3912-4018, 2024.
NATALE, F. et al. The increasing problem of resistant hypertension: we’ll manage till help comes! Medical Sciences, v. 12, n. 4, p. 53, 2024.
PARANJPE, R. et al. Adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments among older patients. Journal of the American Pharmacists Association, v. 62, n. 4, p. 1351-1358, 2022.
PARATI, G. et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension, v. 77, n. 2, p. 692-705, 2021.
PERESUODEI, T. S.; GILL, A.; ORJI, C.; REGHEFAOUI, M.; PALACIOS, M. S. S.; NATH, T. S. A comparative study of the safety and efficacy between ACEIs and ARBs in the management of hypertension: a systematic review. Journal of Hypertension Research (PMC), 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10944326/. Acesso em: 18 set. 2025.
SMITH, D. K.; LENNON, R. P.; CARLSGAARD, P. B. Managing hypertension using combination therapy.American Family Physician, v. 101, n. 6, p. 341-349, 2020.SOBHY, M.; ELETRIBY, A.; RAGY, H.; KANDIL, H.; SALEH, M. A.; FARAG, N.;GUINDY, R.; BENDARY, A.; NAYEL, A. M. E.; SHAWKY, A.; KHAIRY, A.; MORTADA, A.; ZARIF, B.; BADRAN, H.; KHORSHID, H.; MAHMOUD, K.; LEON, K.; ABDELSABOUR, M.; TAWFIK, M.; ABDELMEGID, M. A. F.; KORIEM, M.; LOUTFI, M.; WADIE, M.; ELNOAMANY, M.; SADAKA, M.; SELEEM, M.; ZAHRAN, M.; AMIN, O. A.; AYAD, S.; EL KILANY, W.; AMMAR, W.; ELAWADY, W.; ELHAMMADY, W.;ABDELHADY, Y. ACE inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian cardiology expert consensus in collaboration with the CVREP Foundation. Cardiology and Therapy, 2024.Disponível em: https://link.springer.com/article/10.1007/s40119-024-00381-6. Acesso em: 18 set. 2025.
WORLD HEALTH ORGANIZATION. Global report on hypertension: the race against a silent killer. Geneva: WHO, 2023. Disponível em: https://www.who.int/publications/i/item/9789240081062. Acesso em: 15 nov. 2024.
ZENG, W.; WANG, T.; STÜRMER, T.; HE, N.; SHEN, P.; LIN, H.; GUAN, X.; XU, Y. Comparative effectiveness of ACE inhibitors vs ARBs among older patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2025. Disponível em: https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02753-1. Acesso em: 18 set. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Arthur de Castro Rego, João Victor Torres Lima, Pedro Simão da Silva Azevedo (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
"Os Autores que publicam nesta revista concordam com os seguintes termos:
-
Os Autores mantêm os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a licença Creative Commons Attribution 4.0 International (CC BY 4.0). Esta licença permite que o trabalho seja compartilhado, copiado e adaptado em qualquer suporte ou formato, para qualquer fim, inclusive comercial, desde que seja atribuído o devido crédito de autoria e de publicação inicial nesta revista.
-
Os Autores têm autorização para assumir compromissos contratuais adicionais separadamente, para a distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
-
A revista permite e incentiva os autores a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) após o processo de edição e publicação, pois isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado."
